Incyte

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 2.5K

Market Cap: $12.6B

Website

Introduction: Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials

Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease

Conditions: STAT1 Gain-of-Function Disease

First Posted Date: 2022-09-30

Last Posted Date: 2024-06-06

Lead Sponsor: Incyte Corporation

Registration Number: NCT05561985

Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)

Conditions: Chronic Graft Vs. Host Disease

First Posted Date: 2022-09-16

Last Posted Date: 2024-08-15

Lead Sponsor: Incyte Corporation

Registration Number: NCT05544032

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis (AD)

Interventions: Drug: Ruxolitinib Cream

First Posted Date: 2022-07-13

Last Posted Date: 2024-07-15

Lead Sponsor: Incyte Corporation

Target Recruit Count: 103

Registration Number: NCT05456529

Locations: 🇺🇸
Arlington Research Center, Arlington, Texas, United States
🇺🇸
First Oc Dermatology, Fountain Valley, California, United States
🇺🇸
Dermatology Research Associates, Los Angeles, California, United States

and more 35 locations

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

Phase 3

Recruiting

Conditions: Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions: Drug: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2022-06-23

Last Posted Date: 2024-12-09

Lead Sponsor: Incyte Corporation

Target Recruit Count: 81

Registration Number: NCT05429268

Locations: 🇧🇬
Medical University Plovdiv, Plovdiv, Bulgaria
🇧🇬
Acibadem Cityclinica Mhat Tokuda, Sofia, Bulgaria
🇧🇬
Umhat Alexandrovska Sofia, Sofia, Bulgaria

and more 58 locations

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Phase 2

Completed

Conditions: Glioblastoma
Adult-type Diffuse Gliomas

Interventions: Drug: Pemigatinib

First Posted Date: 2022-03-04

Last Posted Date: 2024-12-20

Lead Sponsor: Incyte Corporation

Target Recruit Count: 83

Registration Number: NCT05267106

Locations: 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸
East Carolina University, Greenville, North Carolina, United States
🇺🇸
University of Illinois Hospital & Health Sciences System, Chicago, Illinois, United States

and more 75 locations

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Pemigatinib

First Posted Date: 2022-02-24

Last Posted Date: 2024-08-06

Lead Sponsor: Incyte Corporation

Target Recruit Count: 8

Registration Number: NCT05253807

Locations: 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸
Florida Cancer Specialists & Research Institute, Fort Myers, Florida, United States

and more 33 locations

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

Phase 2

Completed

Conditions: Vitiligo

Interventions: Drug: Ruxolitinib 1.5% cream
Device: NB-UVB phototherapy

First Posted Date: 2022-02-21

Last Posted Date: 2024-02-08

Lead Sponsor: Incyte Corporation

Target Recruit Count: 55

Registration Number: NCT05247489

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
First Oc Dermatology, Fountain Valley, California, United States
🇺🇸
Principle Research Solutions, Spokane, Washington, United States

and more 10 locations

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: INCB0123667

First Posted Date: 2022-02-14

Last Posted Date: 2023-12-27

Lead Sponsor: Incyte Corporation

Target Recruit Count: 340

Registration Number: NCT05238922

Locations: 🇺🇸
Carolina Bio-Oncology Institute, Pllc, Huntersville, North Carolina, United States
🇫🇷
Centre Leon Berard, Lyon, France
🇮🇹
Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore, Rome, Italy

and more 31 locations

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

Phase 3

Withdrawn

Conditions: Chronic Hand Eczema (CHE)

Interventions: Drug: Vehicle
Drug: Ruxolitinib cream

First Posted Date: 2022-02-10

Last Posted Date: 2022-11-10

Lead Sponsor: Incyte Corporation

Registration Number: NCT05233410

Locations: 🇵🇱
Etg Warszawa, Warsaw, Poland
🇩🇪
Universitaetsklinikum Schleswig Holstein - Campus Luebeck, Luebeck, Germany
🇩🇪
Gemeinschaftspraxis, Mahlow, Germany

and more 35 locations

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

Phase 1

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Tafasitamab
Drug: Lenalidomide

First Posted Date: 2022-02-03

Last Posted Date: 2024-08-09

Lead Sponsor: Incyte Corporation

Target Recruit Count: 53

Registration Number: NCT05222555

Locations: 🇨🇿
Vseobecna Fakultni Nemocnice V Praze, Praha, Czechia
🇨🇿
Fakultni nemocnice v Motole, Praha, Czechia
🇨🇿
Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia

and more 59 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy